Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo.

Regulatory T cells (T(reg)) are currently being tested in clinical trials as a potential therapy in cell and solid organ transplantation. The immunosuppressive drug rapamycin has been shown to preferentially promote T(reg) expansion. Here, we hypothesized that adjunctive rapamycin therapy might pote...

Cijeli opis

Bibliografski detalji
Glavni autori: Hester, J, Schiopu, A, Nadig, SN, Wood, K
Format: Journal article
Jezik:English
Izdano: 2012